Publications by authors named "David A Roth"

Claim this Profile
P
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.
Amy E DeZern, Sylvain Thepot, Stephane de Botton, Andrea Patriarca, Dries Deeren, David A Roth

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia.
Farhad Ravandi, Sravanti Rangaraju, Hagop Kantarjian, Guillermo Garcia-Manero, Musa Yilmaz, David A Roth

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.
Cynthia Aranow, Cornelia F Allaart, Zahir Amoura, Ian N Bruce, Patricia C Cagnoli, David A Roth

Ann Rheum Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
Eline J Arends, Mihaela Zlei, Christopher M Tipton, Jasna Cotic, Zgjim Osmani, David A Roth

Rheumatology (Oxford)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wildland-urban interface wildfire increases metal contributions to stormwater runoff in Paradise, California.
Lauren J Magliozzi, Sandrine J Matiasek, Charles N Alpers, Julie A Korak, Diane McKnight, David A Roth

Environ Sci Process Impacts· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with gene overexpression.
Eytan M Stein, Stephane de Botton, Thomas Cluzeau, Arnaud Pigneux, Jane L Liesveld, David A Roth

Leuk Lymphoma· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses.
Jie Zheng, Jieruo Gu, Yin Su, Yang Li, Xingfu Li, David A Roth

Mod Rheumatol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel J Cook, Philippe Rousselot, David A Roth

Blood Adv· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
Xueqing Yu, Nan Chen, Jun Xue, Chi Chiu Mok, Sang-Cheol Bae, David A Roth

Am J Kidney Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data.
David D'Cruz, Gina Eriksson, Yulia Green, Anne Hammer, Beulah Ji, David A Roth

Lupus Sci Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports.
Michelle Petri, Helain Landy, Megan E B Clowse, Kim Gemzoe, Munther Khamashta, David A Roth

Ann Rheum Dis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study.
Yoshiya Tanaka, Paula Curtis, Kathleen DeRose, Regina Kurrasch, Kyoko Kinoshita, David A Roth

Mod Rheumatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bottled water contaminant exposures and potential human effects.
Paul M Bradley, Kristin M Romanok, Kelly L Smalling, Michael J Focazio, Nicola Evans, David A Roth

Environ Int· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contaminant Exposure and Transport from Three Potential Reuse Waters within a Single Watershed.
Jason R Masoner, Dana W Kolpin, Isabelle M Cozzarelli, Paul M Bradley, Brian B Arnall, David A Roth

Environ Sci Technol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.
Xavier Mariette, Francesca Barone, Chiara Baldini, Hendrika Bootsma, Kenneth L Clark, David A Roth

JCI Insight· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
Murray B Urowitz, Cynthia Aranow, Yumi Asukai, Damon L Bass, Ian N Bruce, David A Roth

Arthritis Care Res (Hoboken)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data.
Daniel J Wallace, Tatsuya Atsumi, Mark Daniels, Anne Hammer, Paige Meizlik, David A Roth

Lupus· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
Richard Furie, Brad H Rovin, Frédéric Houssiau, Gabriel Contreras, Y K Onno Teng, David A Roth

Clin J Am Soc Nephrol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMBRACE: One Small Story in Lupus-One Giant Challenge in Clinical Trials.
Saira Z Sheikh, Tessa R Englund, Susan W Burriss, Jonca Bull, Anya Harry, David A Roth

ACR Open Rheumatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort.
Selin Cooper Blenkinsopp, Qinggong Fu, Yulia Green, Anuradha Madan, Patricia Juliao, David A Roth

Lupus Sci Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.
Fengchun Zhang, Jie Zheng, Yang Li, Guochun Wang, Mingjun Wang, David A Roth

RMD Open· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
Brad H Rovin, Richard Furie, Y K Onno Teng, Gabriel Contreras, Ana Malvar, David A Roth

Kidney Int· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE.
Herbert Struemper, Milena Kurtinecz, Lisa Edwards, William W Freimuth, David A Roth

Lupus Sci Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Sang-Cheol Bae, Damon L Bass, Myron Chu, Paula Curtis, Richard Dimelow, David A Roth

Arthritis Res Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Watershed-Scale Risk to Aquatic Organisms from Complex Chemical Mixtures in the Shenandoah River.
Larry B Barber, Kaycee E Faunce, David W Bertolatus, Michelle L Hladik, Jeramy R Jasmann, David A Roth

Environ Sci Technol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis